Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Sort descending Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Vesicare Solifenacin succinate Bladder, overactive List with clinical criteria and/or conditions Complete
VesiFlow Solifenacin succinate / tamsulosin hydrochloride Benign prostatic hyperplasia Withdrawn
Sogroya somapacitan Growth Hormone Deficiency (GHD) Reimburse with clinical criteria and/or conditions Complete
Ngenla somatrogon Growth hormone deficiency Reimburse with clinical criteria and/or conditions Complete
Genotropin Somatropin Growth hormone deficiency, adult List with criteria/condition Complete
Genotropin Somatropin Growth hormone deficiency, children List with criteria/condition Complete
Genotropin Somatropin Turner Syndrome List with criteria/condition Complete
Omnitrope Somatropin (rDNA origin) Growth hormone deficiency in children and adults N/A Complete
Odomzo Sonidegib Basal Cell Carcinoma Do not reimburse Complete
Nexavar Sorafenib Metastatic Progressive Differentiated Thyroid Carcinoma (DTC) Do not reimburse Complete